Please select the option that best describes you:
Would you use olaparib after progression on an ARPI for a patient with somatic PALB2 mutated mCRPC?
Given the limited # of patients with PALB2 mutation on the PROfound trial (de Bono et al., PMID 32343890) and the benefit primarily driven by Cohort A.
Answer from: Medical Oncologist at Academic Institution
Yes, I would consider using olaparib monotherapy in a sPALB2-altered patient who has previously received one or more ARPI agents. This is based on a recent meta-analysis conducted by the FDA. In that paper, in PALB2-mutated mCRPC patients (N total = 41) rPFS HR was 0.52 (0.23 to 1.17) and OS HR was ...
Sign in or Register to read more